Skip to main content

Drug Interactions between duloxetine and Methadone Diskets

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

methadone DULoxetine

Applies to: Methadone Diskets (methadone) and duloxetine

MONITOR CLOSELY: Coadministration of duloxetine and methadone may result in increased plasma concentrations of both drugs. The proposed mechanism is inhibition of CYP450 2D6 methadone metabolism by duloxetine. In one case report, a patient who had been receiving methadone 50 mg/day for approximately eight years for the treatment of heroin dependence complained of subjective symptoms of opioid overdose (sweating, drowsiness, fatigability, pruritus) a few days after the addition of duloxetine 60 mg/day. The symptoms improved immediately when the dosage of methadone was reduced to 40 mg/day two weeks later, and there was no recurrence when the dosage was increased back to 50 mg/day after two months. Although not reported in this patient, high plasma levels of methadone have been associated with QT interval prolongation and torsade de pointes arrhythmia.

Theoretically, duloxetine systemic exposure may also be increased by methadone. High plasma levels of duloxetine may increase the risk of serious adverse effects such as hypertension, hypertensive crisis, increased heart rate, orthostatic hypotension, syncope, and serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.

MANAGEMENT: Caution is advised if duloxetine and methadone are prescribed in combination. Pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of duloxetine in patients who are stabilized on their methadone regimen. Patients should be advised to report excessive drowsiness, nausea, or asthenia to their physician, and to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope. Likewise, pharmacologic response to duloxetine should be monitored more closely whenever methadone is added to or withdrawn from therapy, and the dosage adjusted as necessary.

References (12)
  1. (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company
  2. McCance-Katz EF, Sullivan LE, Nallani S (2010) "Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review." Am J Addict, 19, p. 4-16
  3. McCance-Katz EF, Mandell TW (2010) "Drug interactions of clinical importance with methadone and buprenorphine." Am J Addict, 19, p. 2-3
  4. Vorspan F, Ksouda K, Bloch V, et al. (2010) "A case report of transient but clinically relevant interaction between methadone and duloxetine: a reply to McCance-Katz et al." Am J Addict, 19, p. 458-9
  5. (2023) "Product Information. Methadone Hydrochloride (methadone)." SpecGx LLC
  6. (2023) "Product Information. Methadose (methadone)." Mallinckrodt Medical Inc
  7. (2024) "Product Information. Methadone (methadone)." Martindale Pharmaceuticals Ltd
  8. (2023) "Product Information. Physeptone (methadone)." Martindale Pharmaceuticals Ltd
  9. (2023) "Product Information. Metharose (methadone)." Rosemont Pharmaceuticals Ltd
  10. Klein MG, Krantz MJ, Fatima N, et. al. (2022) "Methadone Blockade of Cardiac Inward Rectifier K+ Current Augments Membrane Instability and Amplifies U Waves on Surface ECGs: A Translational Study" J Am Heart Assoc, 11, p. 1-13
  11. (2023) "Product Information. methADONe (AFT) (methADONe)." AFT Pharmaceuticals Pty Ltd
  12. (2022) "Product Information. Apo-Methadone (methadone)." Apotex Inc

Drug and food interactions

Major

methadone food

Applies to: Methadone Diskets (methadone)

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of methadone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of methadone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. In 8 study subjects stabilized on methadone maintenance treatment, ingestion of regular strength grapefruit juice (200 mL one-half hour before and 200 mL simultaneously with the daily methadone dose) for five days resulted in an approximately 17% mean increase in methadone peak plasma concentration (Cmax) and systemic exposure (AUC) and a 14% mean decrease in apparent clearance for both the R(+) and S(-) enantiomers. Grapefruit juice did not affect the time to peak level (Tmax), terminal half-life, or apparent volume of distribution of methadone. No signs or symptoms of methadone toxicity or changes in intensity of withdrawal symptoms were reported in the study. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict. In addition, high dosages (particularly above 200 mg/day) and high serum levels of methadone have been associated with QT interval prolongation and torsade de pointes arrhythmia.

MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with methadone. Any history of alcohol or illicit drug use should be considered when prescribing methadone, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. In addition, patients treated with oral methadone should preferably avoid or limit the consumption of grapefruit juice, particularly during the induction of maintenance treatment. Given the interindividual variability in the pharmacokinetics of methadone, a significant interaction with grapefruit juice in certain patients cannot be ruled out. Patients should be advised to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

References (11)
  1. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF (1996) "Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes." Chem Res Toxicol, 9, p. 365-73
  2. Oda Y, Kharasch ED (2001) "Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation." J Pharmacol Exp Ther, 298, p. 1021-32
  3. Benmebarek M, Devaud C, Gex-Fabry M, et al. (2004) "Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone." Clin Pharmacol Ther, 76, p. 55-63
  4. Foster DJ, Somogyi AA, Bochner F (1999) "Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4." Br J Clin Pharmacol, 47, p. 403-12
  5. (2023) "Product Information. Methadone Hydrochloride (methadone)." SpecGx LLC
  6. (2023) "Product Information. Methadose (methadone)." Mallinckrodt Medical Inc
  7. (2024) "Product Information. Methadone (methadone)." Martindale Pharmaceuticals Ltd
  8. (2023) "Product Information. Physeptone (methadone)." Martindale Pharmaceuticals Ltd
  9. (2023) "Product Information. Metharose (methadone)." Rosemont Pharmaceuticals Ltd
  10. (2023) "Product Information. methADONe (AFT) (methADONe)." AFT Pharmaceuticals Pty Ltd
  11. (2022) "Product Information. Apo-Methadone (methadone)." Apotex Inc
Moderate

DULoxetine food

Applies to: duloxetine

GENERALLY AVOID: Use of duloxetine in conjunction with chronic alcohol consumption may potentiate the risk of liver injury. Duloxetine alone can increase serum transaminase levels. In clinical trials, 0.3% of patients discontinued duloxetine due to liver transaminase elevations. The median time to detection was about two months. Three duloxetine-treated patients had liver injury as manifested by transaminase and bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, which may have contributed to the abnormalities observed. Duloxetine does not appear to enhance the central nervous system effects of alcohol. When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol.

MANAGEMENT: Due to the risk of liver injury, patients prescribed duloxetine should be counseled to avoid excessive use of alcohol. Duloxetine should generally not be prescribed to patients with substantial alcohol use.

References (1)
  1. (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.